[1] Watkins PB. Biomarkers for drug-induced liver injury. In: Kaplowitz N,Deleve LD. Drug-induced liver disease,3rd ed. San Diego:Academic Press,2013: 275-286.
[2] Watkins PB,Seligman PJ,Pears JS,et al. Using controlled clinicaltrials to learn more about acute drug-induced liver injury. Hepatology,2008,48（5）:1680-1689.
[3] Daly AK,Day CP. Genetic factors in the pathogenesis of drug-induced liver injury. In:Kaplowitz N,Deleve LD. Drug-induced liver disease,3rd ed. San Diego:Academic Press,2013:215-225.
[4] Olson S,Robinson S,Giffin R. Accelerating the development of biomarkers for drug safety:Workshop summary. http://wwwiomedu/Reports/2009/BiomarkersDrugSafetyaspx.
[5] Jones DP,Lemasters JJ,Han D, et al. Mechanisms of pathogenesis in drug hepatotoxicity putting thestress on mitochondria. Mol Interv,2010,10（2）:98-111.
[6] Daly AK,Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev,2012,44（1）:116-126.
[7] Chalasani NP,Hayashi PH,Bonkovsky HL,et al. ACG clinical guideline:The diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol,2014,109（7）:950-966.
[8] Radi ZA,Koza-Taylor PH,Bell RR,et al. Increased serumenzyme levels associated with Kupffer cell reduction with nosigns of hepatic or skeletal muscle injury. Am J Pathol,2011,179（1）:240-247.
[9] Thulin P,Rafter I,Stockling K,et al. PPARalpha regulates thehepatotoxic biomarker alanine aminotransferase （ALT1） geneexpression in human hepatocytes. Toxicol Appl Pharmacol,2008,231（1）:1-9.
[10] Guidance for Industry: Drug-induced liver injury: PremarketingClinical Evaluation. 2009. （http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf）.
[11] 胡锡祺. 药物性肝损伤组织病理学评分探讨. 中华肝脏病杂志,2012,20（3）:176-177.
[12] Rockey DC,Seeff LB,Rochon J,et al. Causality assessment in drug-induced liver injury usinga structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method. Hepatology,2010,51（6）:2117-2126.
[13] Fannin RD,Russo M,O'Connell TM,et al. Acetaminophen dosing of humans results in blood transcriptome and metabolomechanges consistent with impaired oxidative phosphorylation. Hepatology, 2010,51（1）:227-236.
[14] Su YW,Chen X,Jiang ZZ,et al. A panel of serum microRNAs as specificbiomarkers for diagnosis of compound-and herb-induced liver injury in rats. PLoS One,2012,7（5）:e37395.
[15] Bala S,Petrasek J,Mundkur S,et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced,and inflammatory liver diseases. Hepatology,2012,56（5）:1946-1957.
[16] Antoine DJ,Dear JW,Lewis PS,et al. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital.Hepatology,2013,58（2）:777-787.
[17] Watkins PB,Desai M,Berkowitz SD,et al. Evaluation of drug-induced serious hepatotoxicity（eDISH）:application of this dataorganization approach to phase III clinical trials of rivaroxabanafter total hip or knee replacement surgery. Drug Saf, 2011, 34（3）:243-252. |
